MSD and the European Organisation for Research and Treatment of Cancer (EORTC) have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival (RFS) in patients with high-risk stage III melanoma.Original Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.